Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR14718] to Legumain
- Suitable for: WB
- Reacts with: Mouse, Rat, Human
Product nameAnti-Legumain antibody [EPR14718]
See all Legumain primary antibodies
DescriptionRabbit monoclonal [EPR14718] to Legumain
Tested applicationsSuitable for: WBmore details
Species reactivityReacts with: Mouse, Rat, Human
Recombinant fragment within Human Legumain aa 200-350. The exact sequence is proprietary.
Database link: Q99538
- Human fetal kidney lysate; JAR, HeLa and 293 cell lysates.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.
Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.
We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.
In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.
We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.
Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.
Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferpH: 7.2
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Concentration information loading...
PurityProtein A purified
Our Abpromise guarantee covers the use of ab183028 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/10000 - 1/50000. Predicted molecular weight: 49 kDa.|
FunctionHas a strict specificity for hydrolysis of asparaginyl bonds. Can also cleave aspartyl bonds slowly, especially under acidic conditions. May be involved in the processing of proteins for MHC class II antigen presentation in the lysosomal/endosomal system.
Tissue specificityUbiquitous. Particularly abundant in kidney, heart and placenta.
Sequence similaritiesBelongs to the peptidase C13 family.
- Information by UniProt
- AEP antibody
- Asparaginyl endopeptidase antibody
- cysteine 1 antibody
All lanes : Anti-Legumain antibody [EPR14718] (ab183028) at 1/10000 dilution
Lane 1 : Human fetal kidney lysate
Lane 2 : JAR cell ysate
Lane 3 : HeLa cell lysate
Lane 4 : 293 cell lysate
Lysates/proteins at 20 µg per lane.
Predicted band size: 49 kDa
Exposure time: 3 minutes
Actual band at: 36kDa, 46kDa, 56kDa
ab183028 has been referenced in 2 publications.
- Wang C et al. Lysophosphatidic acid induces neuronal cell death via activation of asparagine endopeptidase in cerebral ischemia-reperfusion injury. Exp Neurol 306:1-9 (2018). WB ; Rat . PubMed: 29673933
- Završnik J et al. Cystatin C deficiency suppresses tumor growth in a breast cancer model through decreased proliferation of tumor cells. Oncotarget 8:73793-73809 (2017). PubMed: 29088746